Search results for "Cement"

showing 10 items of 2662 documents

Molecular bases of the poor response of liver cancer to chemotherapy

2018

Summary A characteristic shared by most frequent types of primary liver cancer, i.e., hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) in adults, and in a lesser extent hepatoblastoma (HB) mainly in children, is their high refractoriness to chemotherapy. This is the result of synergic interactions among complex and diverse mechanisms of chemoresistance (MOC) in which more than 100 genes are involved. Pharmacological treatment, although it can be initially effective, frequently stimulates the expression of MOC genes, which results in the relapse of the tumor, usually with a more aggressive and less chemosensitive phenotype. Identification of the MOC genetic signature accounting fo…

0301 basic medicineHepatoblastomaCarcinoma HepatocellularGenetic enhancementmedicine.medical_treatmentCholangiocarcinoma03 medical and health sciences0302 clinical medicineHumansMedicinecholangiocarcinoma; hepatoblastoma; hepatocellular carcinoma; multidrug resistance; targeted therapies; hepatology; gastroenterologyChemotherapyHepatologybusiness.industryLiver NeoplasmsGastroenterologymedicine.diseasePhenotypeResistome030104 developmental biologyDrug Resistance Neoplasm030220 oncology & carcinogenesisHepatocellular carcinomaCancer cellCancer researchbusinessLiver cancerClinics and Research in Hepatology and Gastroenterology
researchProduct

Quality enhancement of multispectral images for skin cancer optical diagnostics

2018

Melanoma is the least common but deadliest skin cancer, accounting for only about 1% of all cases, but is the cause of the vast majority of skin cancer death. In some parts of the world, especially among western countries, melanoma is becoming more common every year. The detection of melanoma in early stage can be helpful to cure it. Unfortunately, long ques and high prices for dermatology service can result in the skin cancer diagnosis at its later stage, thus increasing the risk of mortality for the patient. It is important to provide a non-invasive optical device for primary care physicians to help diagnose different skin malformation based on obtained optical images. Such device will be…

0301 basic medicineImage qualityComputer sciencebusiness.industrymedia_common.quotation_subjectMultispectral imagemedicine.disease01 natural sciencesField (computer science)Quality enhancement010309 opticsImage stabilization03 medical and health sciences030104 developmental biology0103 physical sciencesmedicineComputer visionQuality (business)Artificial intelligenceSkin cancerImage sensorbusinessmedia_commonOptics, Photonics, and Digital Technologies for Imaging Applications V
researchProduct

Myofilament function and body mass index.

2017

Body mass is reported to influence myocardial performance. Recent studies have emphasised the importance of negative inotropic adipocyte-derived factors and their impact on cardiac contractile function. However, the underlying mechanisms remain unclear. We aimed to determine whether body mass impacts cardiac force development on the level of the contractile apparatus. We examined the influence of body mass index (BMI) (3 groups: group I >25, group II 25–30, group III >30) on the myocardial performance of skinned muscle fibres. Right atrial tissue preparations of 70 patients undergoing aortocoronary bypass operation (CABG, 48 patients, group a) and aortic valve replacement (AVR, 22 patients,…

0301 basic medicineInotropeCardiac function curveMyofilamentmedicine.medical_specialtyobesitybody mass index030204 cardiovascular system & hematologyBiologyBioinformaticsGroup AcontractilityGeneral Biochemistry Genetics and Molecular BiologyContractility03 medical and health sciences0302 clinical medicineAortic valve replacementInternal medicinemedicineClinical significanceGeneral Pharmacology Toxicology and PharmaceuticsmyofilamentsGeneral Neuroscienceskinned fibersGeneral MedicineArticlesmedicine.disease030104 developmental biologyCardiologyBody mass indexBiomedical reports
researchProduct

Aging and serum exomiR content in women-effects of estrogenic hormone replacement therapy.

2017

AbstractExosomes participate in intercellular messaging by transporting bioactive lipid-, protein- and RNA-molecules and -complexes. The contents of the exosomes reflect the physiological status of an individual making exosomes promising targets for biomarker analyses. In the present study we extracted exosome microRNAs (exomiRs) from serum samples of premenopausal women (n = 8) and monozygotic postmenopausal twins (n = 10 female pairs), discordant for the use of estrogenic hormone replacement therapy (HRT), in order to see whether the age or/and the use of HRT associates with exomiR content. A total of 241 exomiRs were detected by next generation sequencing, 10 showing age, 14 HRT and 10 a…

0301 basic medicineMICRORNASTranscriptomeMedicineGene Regulatory NetworksMultidisciplinaryEstradiolmicroRNAEstrogen Replacement TherapyEndocrine system and metabolic diseasesHigh-Throughput Nucleotide Sequencingta3141Middle AgedMenopausePostmenopauseDISCORDANTPOSTMENOPAUSAL WOMENTransgender hormone therapymiRNAsBiomarker (medicine)SKELETAL-MUSCLEFemaleAdultEXPRESSIONmedicine.medical_specialtyMENOPAUSEBODY-COMPOSITIONexosomesta3111ExosomeArticleestrogenic hormone replacement therapy03 medical and health sciencesBreast cancerInternal medicineHumansBREAST-CANCERbusiness.industryta1184Gene Expression ProfilingReproducibility of Resultsbiomarkersmedicine.diseaseGene expression profilingMONOZYGOTIC TWIN PAIRS030104 developmental biologyEndocrinologyPremenopauseCELLSNext-generation sequencing3111 Biomedicinemikro-RNAbusinessTranscriptomeHormone
researchProduct

The Older Finnish Twin Cohort : 45 Years of Follow-up

2019

AbstractThe older Finnish Twin Cohort (FTC) was established in 1974. The baseline survey was in 1975, with two follow-up health surveys in 1981 and 1990. The fourth wave of assessments was done in three parts, with a questionnaire study of twins born during 1945–1957 in 2011–2012, while older twins were interviewed and screened for dementia in two time periods, between 1999 and 2007 for twins born before 1938 and between 2013 and 2017 for twins born in 1938–1944. The content of these wave 4 assessments is described and some initial results are described. In addition, we have invited twin-pairs, based on response to the cohortwide surveys, to participate in detailed in-person studies; these …

0301 basic medicineMaleAgingHORMONE-REPLACEMENT THERAPYphysical activityBLOOD-PRESSURECohort Studies0302 clinical medicineSurveys and QuestionnairesTwins Dizygotickohonnut verenpaineMedicinekohorttitutkimusGenetics (clinical)FinlandBiological Specimen BanksAged 80 and overalcohol1184 Genetics developmental biology physiologyObstetrics and GynecologytwinsMiddle AgedBiobankPOPULATION-BASED TWINepigenetiikkaDEPRESSIVE SYMPTOMSCohortSKELETAL-MUSCLEFemalefyysinen aktiivisuusCohort studyAdulthypertensionAlcohol DrinkinglongitudinalPhysical activityreviewPAIRS DISCORDANTpitkittäistutkimussmokingENVIRONMENTAL-INFLUENCES03 medical and health sciencesTIME PHYSICAL-ACTIVITYtupakointiDiseases in Twinscohort studyDementiaHumansGENOME-WIDE ASSOCIATIONalkoholi (päihteet)Depressive symptomsQuestionnaire studyAgedkaksostutkimusepigeneticsbusiness.industryagingBaseline surveyTwins Monozygoticmedicine.diseasekaksoset030104 developmental biologyikääntyminenPediatrics Perinatology and Child HealthTELOMERE LENGTHbusiness030217 neurology & neurosurgeryDemographyFollow-Up Studiesdementia
researchProduct

Standardising clinical outcomes measures for adult clinical trials in Fabry disease: A global Delphi consensus.

2021

International audience; Background: Recent years have witnessed a considerable increase in clinical trials of new investigational agents for Fabry disease (FD). Several trials investigating different agents are currently in progress; however, lack of standardisation results in challenges to interpretation and comparison. To facilitate the standardisation of investigational programs, we have developed a common framework for future clinical trials in FD.Methods and findings: A broad consensus regarding clinical outcomes and ways to measure them was obtained via the Delphi methodology. 35 FD clinical experts from 4 continents, representing 3389 FD patients, participated in 3 rounds of Delphi p…

0301 basic medicineMaleDelphi TechniqueEndocrinology Diabetes and Metabolism[SDV]Life Sciences [q-bio]Delphi methodDisease030105 genetics & heredityKidneyBiochemistry0302 clinical medicineEndocrinologyClinical outcomesClinical Trials as TopicGlobosidesTrihexosylceramidesMiddle Aged3. Good healthClinical trialIsoenzymesTreatment OutcomeInclusion and exclusion criteriaSecondary Outcome MeasureFemaleAdultmedicine.medical_specialtyConsensusLysosomal storage disorders03 medical and health sciencesQuality of life (healthcare)Inherited metabolic disordersGeneticsmedicineHumansEnzyme Replacement TherapyIntensive care medicineMolecular BiologyFabry diseaseSphingolipidsbusiness.industryClinical study designmedicine.diseaseFabry diseaseClinical trialDelphi consensusalpha-GalactosidaseQuality of LifeFabry DiseaseGlycolipidsbusiness030217 neurology & neurosurgeryMolecular genetics and metabolism
researchProduct

Performance comparison of two whole genome amplification techniques in frame of multifactor preimplantation genetic testing

2018

Purpose To compare multiple displacement amplification and OmniPlex whole genome amplification technique performance during array comparative genome hybridization (aCGH), Sanger sequencing, SNaPshot and fragment size analysis downstream applications in frame of multifactor embryo preimplantation genetic testing. Methods Preclinical workup included linked short tandem repeat (STR) marker selection and primer design for loci of interest. It was followed by a family haplotyping, after which an in vitro fertilization preimplantation genetic testing (IVF-PGT) cycle was carried out. A total of 62 embryos were retrieved from nine couples with a confirmed single gene disorder being transmitted in t…

0301 basic medicineMalePregnancy RateFertilization in VitroBiology03 medical and health sciencessymbols.namesake0302 clinical medicinePregnancymedicineGeneticsSingle Embryo TransferHumansGenetic TestingAlleleGenetics (clinical)Preimplantation DiagnosisGenetic testingGeneticsWhole Genome AmplificationSanger sequencingComparative Genomic Hybridization030219 obstetrics & reproductive medicinePreimplantation genetic testingSingle gene disordermedicine.diagnostic_testTripeptidyl-Peptidase 1HaplotypeMultiple displacement amplificationObstetrics and GynecologyGeneral MedicineAneuploidyHuman geneticsWhole genome amplification030104 developmental biologyBlastocystReproductive MedicineEmbryosymbolsMicrosatelliteFemaleNucleic Acid Amplification TechniquesDevelopmental BiologyJournal of Assisted Reproduction and Genetics
researchProduct

Impact of elosulfase alfa in patients with morquio A syndrome who have limited ambulation: An open-label, phase 2 study.

2017

Efficacy and safety of elosulfase alfa enzyme replacement therapy (ERT) were assessed in an open-label, phase 2, multi-national study in Morquio A patients aged ≥5 years unable to walk ≥30 meters in the 6-min walk test. Patients received elosulfase alfa 2.0 mg/kg/week intravenously for 48 weeks. Efficacy measures were functional dexterity, pinch/grip strength, mobility in a modified timed 25-foot walk, pain, quality of life, respiratory function, and urine keratan sulfate (KS). Safety/tolerability was also assessed. Fifteen patients received elosulfase alfa, three patients discontinued ERT due to adverse events (two were grade 3 drug-related adverse events, the other was not drug-related), …

0301 basic medicineMaleWalkingchemistry.chemical_compoundGrip strengthGALNS protein0302 clinical medicineElosulfase alfaQuality of lifeActivities of Daily LivingRespiratory functionFunctional abilityChildGenetics (clinical)education.field_of_studyMucopolysaccharidosis IVChondroitinsulfatases3. Good healthRespiratory Function TestsTreatment OutcomeTolerability6.1 PharmaceuticalsOriginal ArticleFemalePatient Safetyphysical enduranceGALNS protein human [supplementary concept]Adultsafetymedicine.medical_specialtyAdolescentClinical Trials and Supportive ActivitiesPopulationClinical Sciences03 medical and health sciencesYoung Adultmobility limitationClinical ResearchInternal medicinemedicineGeneticsHumansEnzyme Replacement TherapyAdverse effecteducationhuman [supplementary concept]Exercisebusiness.industryEvaluation of treatments and therapeutic interventionsOriginal Articles030104 developmental biologychemistryKeratan SulfateQuality of LifeSelf Reportbusiness030217 neurology & neurosurgeryBiomarkers
researchProduct

Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial.

2019

Abstract Background Fabry disease is a rare, X-linked, lifelong progressive lysosomal storage disorder. Severely deficient α-galactosidase A activity in males is associated with the classic phenotype with early-onset, multisystem manifestations evolving to vital organ complications during adulthood. We assessed the ability of 2 low-dose agalsidase beta regimens to lower skin, plasma, and urine globotriaosylceramide (GL-3) levels, and influence clinical manifestations in male pediatric Fabry patients. Methods In this multicenter, open-label, parallel-group, phase 3b study, male patients aged 5–18 years were randomized to receive agalsidase beta at 0.5 mg/kg 2-weekly (n = 16) or 1.0 mg/kg 4-w…

0301 basic medicineMalemedicine.medical_specialtyAbdominal painAdolescentEndocrinology Diabetes and MetabolismGlobotriaosylceramideUrologyRenal function030105 genetics & heredityBiochemistrylaw.invention03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyRandomized controlled triallawBiopsyGeneticsmedicineHumansEnzyme Replacement TherapyChildMolecular BiologySkinKidneymedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryTrihexosylceramidesEnzyme replacement therapymedicine.diseaseFabry diseaseIsoenzymesmedicine.anatomical_structureTreatment OutcomechemistryChild Preschoolalpha-GalactosidaseFabry Diseasemedicine.symptombusiness030217 neurology & neurosurgeryMolecular genetics and metabolism
researchProduct

Lysosomal acid lipase deficiency: Expanding differential diagnosis.

2016

The differential diagnoses for metabolic liver diseases may be challenging in clinical settings, which represents a critical issue for disorders such as lysosomal acid lipase deficiency (LAL-D). LAL-D is caused by deficient activity of the LAL enzyme, resulting in the accumulation of cholesteryl esters and triglycerides throughout the body, predominately in the liver, spleen, gastrointestinal tract, and blood vessel walls. LAL-D is a progressive, multi-organ disease with early mortality and significant morbidity characterized by a combination of hepatic dysfunction and dyslipidemia. Evidence suggests LAL-D may be substantially underdiagnosed or misdiagnosed, which is critical given that dis…

0301 basic medicineMalemedicine.medical_specialtyPathologyAdolescentEndocrinology Diabetes and MetabolismDiseaseLysosomal acid lipase deficiencyBiochemistryGastroenterologyDiagnosis Differential03 medical and health sciences0302 clinical medicineEndocrinologyInternal medicineGeneticsmedicineLysosomal storage diseaseHumansChildMolecular BiologyTriglyceridesNiemann-Pick DiseasesGaucher Diseasebusiness.industryWolman DiseaseInfantEnzyme replacement therapySterol Esterasemedicine.diseaseClinical trial030104 developmental biologyEarly DiagnosisSebelipase alfaDisease Progression030211 gastroenterology & hepatologyFemaleCholesterol EstersDifferential diagnosisbusinessDyslipidemiaMolecular genetics and metabolism
researchProduct